PHARMACYTE BIOTECH, INC. (PMCB) Return on equity 2017–2026
PHARMACYTE BIOTECH, INC. (PMCB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-58.3%FY2026 · since FY2017: -54.9% → -58.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -58.3% | -117.4 pp |
| FY2025 | 59.1% | +57.9 pp |
| FY2024 | 1.2% | +7.1 pp |
| FY2023 | -5.9% | -1.2 pp |
| FY2022 | -4.7% | +48.5 pp |
| FY2021 | -53.2% | +22.0 pp |
| FY2020 | -75.2% | +5.5 pp |
| FY2019 | -80.7% | +37.7 pp |
| FY2018 | -118.4% | -63.4 pp |
| FY2017 | -54.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PMCB financial trends
PMCB RevenuePMCB Net incomePMCB Net marginPMCB Gross profitPMCB Gross marginPMCB Operating incomePMCB Operating marginPMCB Operating cash flowPMCB Free cash flowPMCB Capital expendituresPMCB Stock buybacksPMCB Dividends paidPMCB Total assetsPMCB Total liabilitiesPMCB Shareholders’ equityPMCB overview →